Literature DB >> 15325062

Emerging fungal resistance.

John W Baddley1, Stephen A Moser.   

Abstract

There has been an increase in systemic fungal infections over the past several decades, partially because of an increasing number of critically ill patients, surgical procedures, and immunosuppressive therapies, as well as the use of more invasive diagnostic and therapeutic medical procedures. Concomitant with this increase in infections has been the increase in azole-resistant Candida species and opportunistic molds with intrinsic resistance to many of the currently available antifungal agents. This review focuses on antifungal resistance, with emphasis on emerging resistance patterns and emerging fungi that are intrinsically resistant to antifungal agents.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15325062     DOI： 10.1016/j.cll.2004.05.003

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN： 0272-2712            Impact factor:   1.935


  10 in total

1.  Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Authors:  D Andes; A Forrest; A Lepak; J Nett; K Marchillo; L Lincoln
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.

Authors:  D Andes; A Lepak; J Nett; L Lincoln; K Marchillo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Candida pseudorugosa sp. nov., a novel yeast species from sputum.

Authors:  Juan Li; Ying-Chun Xu; Feng-Yan Bai
Journal:  J Clin Microbiol       Date:  2006-10-04       Impact factor: 5.948

Review 4.  Caspofungin: a review of its use in the treatment of fungal infections.

Authors:  Paul L McCormack; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Burn wound infections.

Authors:  Deirdre Church; Sameer Elsayed; Owen Reid; Brent Winston; Robert Lindsay
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

6.  Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.

Authors:  Marisa H Miceli; Pranatharthi Chandrasekar
Journal:  Infect Drug Resist       Date:  2012-01-11       Impact factor: 4.003

7.  Guideline for diagnosis, prophylaxis and treatment of invasive fungal infection post burn injury in China 2013.

Authors:  Gaoxing Luo; Jianglin Tan; Yizhi Peng; Jun Wu; Yuesheng Huang; Daizhi Peng; Xu Wang; Dahai Hu; Songtao Xie; Guoan Zhang; Chunmao Han; Xiaoyuan Huang; Ciyu Jia; Jiake Chai; Jingning Huan; Guanghua Guo; Jianhua Zhan; Weiguo Xie; Ying Cen; Rong Yu; Huade Chen; Xihua Niu; Yibing Wang; Jinfeng Fu; Baosheng Xue
Journal:  Burns Trauma       Date:  2014-04-06

Review 8.  Micafungin: an evidence-based review of its place in therapy.

Authors:  Pola de la Torre; Annette C Reboli
Journal:  Core Evid       Date:  2014-02-25

9.  Trans-chalcone and quercetin down-regulate fatty acid synthase gene expression and reduce ergosterol content in the human pathogenic dermatophyte Trichophyton rubrum.

Authors:  Tamires Aparecida Bitencourt; Tatiana Takahasi Komoto; Bruna Gabriele Massaroto; Carlos Eduardo Saraiva Miranda; Rene Oliveira Beleboni; Mozart Marins; Ana Lúcia Fachin
Journal:  BMC Complement Altern Med       Date:  2013-09-17       Impact factor: 3.659

10.  Functional analysis of Paracoccidioides brasiliensis 14-3-3 adhesin expressed in Saccharomyces cerevisiae.

Authors:  Patricia Akemi Assato; Julhiany de Fátima da Silva; Haroldo Cesar de Oliveira; Caroline Maria Marcos; Danuza Rossi; Sandro Roberto Valentini; Maria José Soares Mendes-Giannini; Cleslei Fernando Zanelli; Ana Marisa Fusco-Almeida
Journal:  BMC Microbiol       Date:  2015-11-04       Impact factor: 3.605
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.